Note:Site of Care Utilization Management Policy applies for teprotumumab-trbw (Tepezza). For information on site of service, seeUtilization Management Policy on Site of Care for Specialty Drug Infusions. Exclusions Aetna will not provide coverage for repeat series of Tepezza infusions. Prescriber Sp...
Coverage for speech therapy benefits under traditional plans range from a defined number of visits per year to unlimited benefits. Benefit levels are determined by the particular benefit plan selected by the employer or contract holder. Please check benefit plan descriptions for details. Most Aetna pl...
and Policy Promoting EDI in Genetics Research PTSD and Cardiovascular Disease Red Blood Cell Transfusion: 2023 AABB International Guidelines Reimagining Children’s Rights in the US Spirituality in Serious Illness and Health The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Heal...
GCPGood Coverage Partner(gaming) GCPGroundwater Characterization Project GCPGolden Cheesepie GCPGravier Conseils et Participations(French: Tips and Gravel Investments) GCPGross Corporate Product(sales and all other revenues) GCPGround Control Position ...
Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies ...
When the period between the end of the treatment coverage of the first dispensation of LABA or LAMA or ICS and the following dispensation of LABA or LAMA or ICS useful to deliver a DT or a TT fell within 30 days, the DT or TT were considered as a MI strategy. The index date was ...
In-country data and country-specific information will be made available to national policy-makers and organizational and implementing partners. A detailed publication and communication plan will be developed that describes the number and types of reports and manuscripts planned for the study and criteria...
on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making View More Latest Conference Coverage...
(microarrays designed to evaluate CNV within transcribed regions) have been designed to target the exon of a single gene, exons within a group of specific disorders, or genome-wide exonic coverage [99,100]. Intragenic deletions/duplications have been identified in a number of autosomal dominant, ...
[5,120]. Currently, some insurance providers in the USA (such as Managed Medicare and Medicaid) have introduced coverage determinations that enable reimbursement of pharmacogenetic testing, and while the number of claims for coverage of pharmacogenetic testing remains low, it has more than doubled ...